$ACXP News

Last published 4d ago

4d agoAMFN CAST BIVI SWRD+5Fusion Power, Global Capital, Branded Streaming and Neurology Breakthroughs: New to The Street Show #779 Premieres Tonight on Bloomberg TelevisionACCESS NewswireThe data center boom needs power that doesn't depend on the grid. Telecom companies want to own the screen their customers already use. International investors are looking to the United States to grow their wealth. And patients with long COVID and Parkinson's disease are waiting for treatments that work. Tonight, New to The Street brings leaders working on each of those problems to a global busine ...
2w agoACXPAcurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business UpdatePR NewswireSTATEN ISLAND, N.Y., Oct. 26, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for
3w agoACXPAcurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class EffectPR NewswirePublication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid in a murine neutropenic thigh infection modelStructural
3w agoACXPACURX PHARMACEUTICALS, INC. ANNUAL MEETING OF STOCKHOLDERS - ACURX PHARMACEUTICALS INCEarnings Call TranscriptsGood morning, everyone. It's my pleasure to welcome you to the 2026 annual meeting of stockholders of Acurex Pharmaceuticals. I'm Bob DeLucia, Executive Chairman of the Board of Directors. It is now 10 a.m. Eastern Time,
1mo agoACXPAcurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile InfectionPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1mo agoACXPAcurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-CulturesPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a late clinical stage biopharmaceutical company developing a new class of antibiotics for...
2mo agoACXPAcurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for IbezapolstatPR NewswireThe proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial
2mo agoACXPAcurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business updatePR NewswireSTATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for
3mo agoACXPJapan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor AntibioticsPR NewswireSTATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule
3mo agoACXPAcurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor AntibioticsPR NewswireAcurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
3mo agoACXPFDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile InfectionPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...
4mo agoACXPAcurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile InfectionPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat...
4mo agoACXPAcurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
4mo agoACXPAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific ConferencePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
6mo agoACXPAcurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
6mo agoACXPAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026PR NewswireAcurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
6mo agoACXPAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company ShowcasePR NewswireAcurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for...
6mo agoACXPAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
6mo agoACXPAcurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
6mo agoACXPAcurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
7mo agoACXPKorean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC InhibitorsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
8mo agoACXPAcurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
8mo agoACXPAcurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile InfectionPR NewswireAcurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
8mo agoACXPAcurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
9mo agoACXPUSPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC InhibitorsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
12mo agoACXPAcurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAcurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority PathogensPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific ConferencePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAustralian Patent Office Grants Acurx Patent for DNA Polymerase IIIC InhibitorsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile InfectionPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoACXPAcurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAcurx Pharmaceuticals, Inc. Announces Reverse Stock SplitPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAcurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross ProceedsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAcurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDIPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific ConferencePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...
1y agoACXPAcurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company ShowcasePR NewswireAcurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule...
1y agoACXPIndian Patent Office Grants Acurx Patent for DNA Polymerase IIIC InhibitorsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI AntibioticsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business UpdatePR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
1y agoACXPAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDIPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPJPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC InhibitorsPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
1y agoACXPAcurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPR NewswireAcurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...